Evidence map›Paper›PMID 40632611›Full record

ArticleOncotarget2025

A novel anti-human CD25 mAb with preferential reactivity to activated T regulatory cells depletes them from the tumor microenvironment.

Maja Buszko, Madalyn Jones, Sruthi Chempati, Lyra Morina, Kirstin Ward, Habtom Habte, Michael Dziegielewski, Ethan M Shevach

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Maja BuszkoLaboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
Madalyn JonesLaboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
Sruthi ChempatiLaboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
Lyra MorinaLaboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
Kirstin WardLaboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
Habtom HabteBoehringer Ingelheim, Ridgefield, CT 06877, USA.
Michael DziegielewskiBoehringer Ingelheim, Ridgefield, CT 06877, USA.
Ethan M ShevachLaboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T

Indexed as

Antibodies, MonoclonalInterleukin-2 Receptor alpha SubunitT-Lymphocytes, RegulatoryTumor MicroenvironmentAnimalsCD8-Positive T-LymphocytesCell Line, TumorCell ProliferationFemaleHumansHybridomasLymphocyte ActivationMiceXenograft Model Antitumor AssaysAntibodies, MonoclonalIL2RA protein, humanInterleukin-2 Receptor alpha SubunitCD25GVHDmAbTMETreg

Identifiers

PMID40632611
PMCPMC12243931

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.